



HLS Therapeutics®

INVESTOR PRESENTATION

Greg Gubitz | CEO

Gilbert Godin | President & COO

Q3 2018


Forward-looking statements

Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always using words or phrases such as “project”, “forecast”, “target”, “expect”, “seek”, “endeavour”, “anticipate”, “plan”, “estimate”, “believe”, “intend”, or stating that certain actions, events or results may, could, should, would, might or will occur or be taken, or achieved) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of known and unknown risks and uncertainties which would cause actual results or events to differ materially from those presently anticipated. A number of factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this presentation. These factors should be considered carefully and prospective investors should not place undue reliance on these forward-looking statements. Although the forward-looking statements contained in this presentation are based upon what HLS currently believes to be reasonable assumptions, HLS cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, HLS does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances.

*** All figures in USD unless otherwise noted.**

Specialty pharma veterans

BIOVAIL PERFORMANCE



Strong record of value creation



Executing
on our vision

Leading healthcare investors behind HLS

HEALTHCOR

\$3.6B AUM

ATHYRIUM

\$3.5B AUM

ORBIMED

\$14B AUM

HLS Therapeutics


\$385M

debt and equity

Refinanced debt post-Q2; ~\$10M in annual savings

HLS's methodical strategy

Staged approach




KEY STRENGTHS

Operational pharma know-how
Business development expertise
Efficient corporate platform
Strong balance sheet

Deploying capital to produce outsized returns

Rapid scale since inception



Comprehensive pharma operations across N. America

¹ net loss adjusted for (i) "stock-based compensation", (ii) "amortization and depreciation", (iii) "acquisition costs", (iv) "finance and related costs", and (v) "provision for (recovery of) income taxes"

Key Highlights Subsequent to Q2

Refinanced Debt

- Lowered principal to \$100M
- Added revolving facility of \$25M
- Reduced interest rate by ~600 basis points
- Will save ~\$10M per year
- Additional loan capacity of \$100M available

Initiated Dividend

- Quarterly dividend of CDN\$0.05
- Return to shareholders of ~\$4M
- Record date October 24, 2018
- Payable on December 14, 2018

Durable cash-flows and promising outlook enable positive developments

Our portfolio

FOUNDATIONAL PRODUCTS

Clozaril	Schizophrenia	U.S./Canada	Acquired 2015	marketed
Absorica	Acne	U.S.	Acquired 2016	marketed by third party

TRANSFORMATIVE PRODUCTS

Vascepa	Hypertriglyceridemia	Canada	In-licensed 2017	pre-filing
Trinomia	CV risk reduction	Canada	In-licensed 2017	pre-filing

Clozaril: Well established antipsychotic in North America

WHO essential medicine

Schizophrenia

1% of population

1/3 patients

refractory to first line treatment

LIFE CHANGING

Clozaril can be life changing,
often the only and last recourse
for refractory patients

80%

response rate

Clozaril

15,000

active patients

US\$29 Million

revs in Canada in 2017

US\$19 Million

revs in U.S. in 2017



Great foundational product with strong consistent cash flow

CSAN: Our patient portal and registry is an economic moat for Clozaril in Canada

Created resilient demand for product

25 dedicated resources

Sales reps

Nurses

Physician consultants

24/7 availability

CSAN: Clozaril Support and Assistance Network


200,000
blood
tests/year

Every week
Follows up on
1,300 patients for
non-compliance

24,000
incoming
calls/year

50,000
calls to
customers/
year

55%
market
share



Growing franchise in a genericized Canadian market

Vascepa: First-in-class cardiovascular product

Only purified Rx Icosapent Ethyl (EPA)


In-licensed from Amarin Corporation (NASDAQ: AMRN)

VASCEPA U.S. INDICATION

HYPERTRIGLYCERIDEMIA

(Very High) (>500 mg/dl)

Vascepa



96%

Other

EPA

DIFFERENTIATION vs LOVAZA

Lowers triglycerides (TG) but
DOES NOT elevate LDL
(bad cholesterol)

Lovaza

(never launched in Canada)
peak sales of US\$960M
before LOE

Lovaza contains
42% DHA which
Elevates LDL
(bad cholesterol)



Transformational anchor to launch our second therapeutic franchise

Vascepa – Exclusive Canadian rights

U.S. MARKET FACTS

13

Quarters of 22% TRx y/y growth


≥\$230M

Amarin 2018 guidance

CANADIAN MARKET TODAY

>500,000

Hypertriglyceridemia patients



Poised to be HLS's top product (based on U.S. sales data)

Vascepa: REDUCE-IT Trial

Evaluating effect of Vascepa in lowering cardiovascular events as an add-on to statin therapy in patients with elevated triglycerides (>150mg/dL)

CV risk factor



1 in 3
U.S. ADULTS HAVE
ELEVATED TG LEVELS

Trial design

8,200 PATIENTS

statin + placebo



statin + Vascepa



Trial impact



16x
increased
addressable
market

Data will be available
prior to Canadian drug
application (Q4/2018)

CV Outcome trial effect

23%

Reduction in risk of
Myocardial Infarction in
HOPE trial

\$400M*

ALTACE sales at peak
post HOPE trial, from
\$20M pre-trial

*TSA-Canada (CAD)

Positive OUTCOME trials drive prescription growth

Trinomia: Expanding our cardiovascular franchise

In-licensed from Ferrer Internacional, S.A. (Spain private)

INDICATION

SECONDARY
PREVENTION OF
CARDIOVASCULAR
EVENTS

Aspirin
(anti-coagulant)



Atorvastatin
(lipid lowering)




Ramipril
(anti-hypertensive)



DIFFERENTIATION

TRI-COMBO CAPSULE
“Polypill”



COMPLIANCE/ADHERENCE IMPROVEMENT

Patients at risk following an initial CV event are poly medicated (7-8 drugs).



Pill burden is biggest reason for non-adherence to treatment

Complementary therapy to cardiovascular franchise


Trinomia: Exclusive Canadian rights

46,000

Rx/month 36 months
post launch (Spain)

30+

countries approved in



Leverages Vascepa sales and marketing infrastructure



Positive tailwinds

Market trends

Balance sheet strength

Organic growth

Robust pipeline

Rich proprietary deal flow

Proprietary deals

Unique approach to acquisitions

BACKGROUND



Makes strategic decision to divest global rights to Clozaril



OUTCOME



HLS Therapeutics®


Negotiated a North American carve out



Rationale:
increased value for
both North America
and ROW

Access and ability to execute growth plans

Strong organic growth built in with rich proprietary deal flow



Significant head room to grow portfolio

Buy right: Our investment criteria

1. Late-stage clinical or commercial
2. Experience in the therapeutic area
3. Ability to compete and win
4. Clinically relevant/differentiated
5. Quality economics driving threshold returns


1

2

3

4


5



Disciplined acquisition strategy

Third leg of HLS's growth strategy

Cash flow/Growth/Explosive growth



KEY CRITERIA

Commercial advantage

Portfolio alignment

Gated financial exposure

Measured risk at the right time

Veteran specialty pharma leadership team

MANAGEMENT

William Wells | Executive Chairman

Former CEO and Director of Biovail

Greg Gubitz | Chief Executive Officer

Former Senior Vice President, Corporate Development and General Counsel of Biovail

Gilbert Godin | President and Chief Operating Officer

Former Executive Vice President and COO of Biovail, CEO of Duchesnay (USA), President of MDS Pharma (USA); VP at Schering-Plough (FR) and L'Oreal

Tim Hendrickson | Chief Financial Officer

Formerly of Cubist Pharmaceuticals; Procter & Gamble; P&G Pharmaceuticals; and Warner Chilcott

Ryan Lennox | General Counsel

Former Senior Counsel at Amgen Inc., where he was responsible for all of the legal affairs of their Canadian affiliate

Dr. Jason Gross | VP, Scientific Affairs

Former VP of Scientific and Medical Affairs at Crown, MDS Capital, and Zenith Goldline, ex-National Institutes of Health (NIH) and Food & Drug Administration (FDA)

Sanjiv Sharma | Chief Commercial Officer

Former SVP Worldwide Commercial & Country Head-US for NicOx; and VP Commercial for Duchesnay USA, Biovail, Aventis

Dr. Hemanth Varghese, PhD | Head of Corporate Strategy and Business Development

Former senior executive with Valeant and Endo in Business Development and in Operations, prior to which he was VP of Business Development for Biovail

BOARD

William Wells | Executive Chairman

Current or former Board roles with: Biovail/Valeant, Medgenesis, ACADIA Pharmaceuticals, EnerCare and Evizone

Greg Gubitz | Director

Former Board roles with: biOasis, Telesta, Drug Royalty and Imperial Plastech

J. Spencer Lanthier | Lead Director

Former Chairman and CEO of KPMG Canada, formerly board member of TMX Group, Torstar Corp., Biovail Corp., Rona Inc., Ellis-Don Inc.

Yvon Bastien | Independent Director

Former CEO of Sanofi Aventis in Canada, formerly held executive positions with Eli Lilly, IMS Canada, Delta Healthcare

Rodney Hill | Independent Director

Chief Risk Officer with OMERS

Daniel Tassé | Independent Director

Chairman and CEO of Alcresta Therapeutics, current Board roles with REGENXBIO and Bellerophon Therapeutics, formerly served as Chairman and CEO of Ikaria

Don DeGolyer | Independent Director


President and CEO of Vertice Pharma, formerly COO with ENDO Pharmaceuticals and Sandoz North America

A business of scale based on two foundational products

With two potentially transformative products on deck


REVENUE*

(\$ millions)



ADJUSTED EBIDTA*¹

(\$ millions)



¹ Net loss adjusted for (i) "stock-based compensation", (ii) "amortization and depreciation", (iii) "acquisition costs", (iv) "finance and related costs", and (v) "provision for (recovery of) income taxes"

Cap table

SUMMARY BALANCE SHEET & CAPITALIZATION

(in USD '000,000's,
unless otherwise noted)

	At Dec 31, 2017	At Jun 30, 2018
Cash and Cash Equivalents	36.2	45.2
Senior Secured Term Loan	151.3	137.9
Net Debt (Term Loan less Cash)	115.1	92.7
Shares Outstanding ('000's)	25,278	27,430

Market Cap at 08/15/18: ~\$235M CDN

SHAREHOLDERS

	Shareholdings*	
	# ('000's)	%
HealthCor	5,500	20.1%
Athyrium	4,125	15.0%
OrbiMed	3,300	12.0%
Janus	2,842	10.4%
Management & Founders**	4,829	17.6%
All other	6,834	24.9%
Total	27,430	100.0%

* Issued and outstanding at 3/27/18; does not include dilutive securities.

** Includes HLS Directors and Officers; four HLS Founders hold 4,713,500 shares (17.2%).

Refinanced Debt; initiated dividend post Q2

Experience

Clear value creating strategy
Cash flow/Growth/Explosive growth

Execution

2 cash flowing assets
2 pre-registration assets
Scalable platform

Opportunity

High organic growth
Strong cash flow and balance sheet
Robust deal flow for acquisitions

